A new immunotherapy strategy based on the administration of ADCs or CAR-T cells derived from a monoclonal antibody specific for the pre-TCR receptor, which impairs LIC activity and tumor progression, has been developed and validated in a preclinical human T-ALL xenotransplantation model in mice.

Inhibitor of Interferon type I (IFN-I) is capable of inhibiting the inflammatory response in those autoimmune diseases in which this cytokine is involved, called interferonopathies, such as systemic lupus erythematosus and Aicardi-Goutières syndrome.